

# Comparing the latest HemoClear blood washing system to a gold standard centrifugal washing system for the preparation of women's own lost blood for safe reinfusion after vaginal deliveries and caesarean sections

<b>Submission date</b> 11/06/2021	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 20/08/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 16/01/2023	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

In the developing world many people don't have access to donated blood products. If they lose a lot of blood, for instance after the delivery of a baby, the safe return of their own blood could be lifesaving. However, in order to safely give back lost blood it should first be washed to get rid of the unwanted components, such as bacteria. A device IS used to clean and purify any lost blood so that it is safe to be given back to the mother after delivery should she need it. In comparison with the current cell salvage device the new HemoClear device is a simple filter that is intended to make cell salvage more affordable and available to all around the world. The aim of this study is to use collected blood lost after vaginal and caesarean deliveries and process it with the new HemoClear device and the currently used blood salvage machine. The study is a non-clinical pilot, meaning that the research staff are only running tests on the collected shed blood in the hospital laboratory, and participation will not have any effect on the clinical care participants will receive.

### Who can participate?

Pregnant women over the age of 18 years

### What does the study involve?

At the time participants are delivering their baby, one of the research team at the hospital will be informed that they are about to have a baby. If they're having a caesarean section, during the operation any lost blood is suctioned into a blood collection reservoir. This is a standard procedure that also occurs outside of the research. Instead of throwing the blood away as normally happens, the research team will add a drug called heparin to the suction container (to stop the blood from clotting) and then after the caesarean was complete, take the suction container for processing and analysis. If participants have an assisted vaginal birth, an under-buttock sterile drape is placed as standard to collect any blood lost for measuring purposes.

Once the baby is born, the blood in the drape is removed and collected in a sterile container for processing and analysis. After tests are performed and the results reported all blood samples will be destroyed. No samples are stored after the completion of the study.

What are the possible benefits and risks of participating?

The blood collected will only be used for investigation in a laboratory to compare the performances of the two devices and will not be given back to participants. There will be no direct health benefits for participants other than to contribute to improved health care for mothers around the world. There also aren't any health disadvantages or risks to participants' health arising from taking part in the study.

Where is the study run from?

Chelsea and Westminster Hospital NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

February 2021 to January 2023

Who is funding the study?

European Commission

Who is the main contact?

Dr Philip Barclay

Philip.barclay@nhs.net

## Contact information

**Type(s)**

Scientific

**Contact name**

Dr Philip Barclay

**ORCID ID**

<https://orcid.org/0000-0001-8278-7182>

**Contact details**

Anaesthetic Department

West Middlesex University Hospital

Twickenham Road

Isleworth

United Kingdom

TW7 6AF

+44 (0)20 8321 6285

Philip.barclay@nhs.net

**Type(s)**

Scientific

**Contact name**

Dr Dion Osemwengie

## Contact details

Dokter Stolteweg 70  
Zwolle  
Netherlands  
8025 AZ  
+31 (0)618 692 328  
dion.osemwengie@hemoclear.com

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### Integrated Research Application System (IRAS)

294144

### Protocol serial number

CPMS 48128, IRAS 294144

## Study information

### Scientific Title

Use of the HemoClear system for obstetric cell salvage: A pre-clinical proof of concept to cleanse blood salvaged in caesarean sections and vaginal delivery

### Study objectives

The simple, accessible, and cost-effective HemoClear blood salvage filter performs equally well as the gold standard centrifugal salvage device in salvaging red blood cells and washing out harmful non-cellular components.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 09/02/2021, Health and Social Care Research Ethics Committee A (HSC REC A; Office for Research Ethics Committees Northern Ireland (ORECNI), Customer Care & Performance Directorate, Unit 4, Lissue Industrial Estate West, Rathdown Walk, Moira Road, Lisburn, BT28 2RF, UK; +44 (0)28 9536 1400; prs@hscni.net), REC ref: 21/NI/0015

### Study design

Observational clinical laboratory study

### Primary study design

Observational

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Vaginal deliveries and caesarean sections

## **Interventions**

Consenting and collecting participants' samples

Consent will be sought from women scheduled that are about to have a caesarean section or go through assisted vaginal delivery. Collection and measure of blood lost at caesarean section and assisted vaginal births is standard practice. Once delivery is complete, the collected blood in the drape will be transferred by a member of the research team for processing. No clinical or demographic data is collected for any participant.

Processing with cell salvage devices

Prior to processing a small volume of each shed blood volume is taken to determine the blood quality by means of several laboratory analyses. Next the shed blood volume collected from each participant is split into two. The first half is processed with a gold standard cell saver device and the second half is processed with the HemoClear device. The processed blood volumes are taken to the laboratory and analyzed as well. Upon completion of the analysis all blood samples will be discarded.

Statistical analysis

To determine the washing effectivity and comparability of the two washing devices, statistical analysis will be performed with the laboratory results.

## **Intervention Type**

Device

## **Phase**

Not Applicable

## **Primary outcome(s)**

The novel HemoClear device's washing efficiency statistical comparability to the gold standard cell saver, measured using the statistical difference in the amounts of blood cells and non-cellular components after processing with HemoClear compared to processing with the gold standard device

## **Key secondary outcome(s)**

1. Percentage of maternal blood cells recovered by each device measured by complete blood counts using a haematology analyser, prior to processing of the shed blood and after processing with each device
2. Percentage of neonatal blood cells recovered by each device measured using the Kleihauer-Betke tests, prior to processing of the shed blood and after processing with each device
3. Percentage of alpha-fetoprotein washed out by each device as a marker of amniotic fluid content measured using a chemistry analyser, prior to processing of the shed blood and after processing with each device
4. Percentage of bacterial load washed out by each device measured using a microbial detection system, prior to processing of the shed blood and after processing with each device
5. Percentage of albumin washed out by each device as a general marker of washing efficiency and removal of proteins, measured using a chemistry analyser, prior to processing of the shed blood and after processing with each device
6. Percentage of lactate dehydrogenase washed out by each device as a market of the amount of dead red blood cells measured using a chemistry analyser, prior to processing of the shed blood and after processing with each device
7. Percentage of heparin washed out by each device as a marker of coagulation, measured using

a coagulometer, prior to processing of the shed blood and after processing with each device  
8. The effect on the coagulation profile of the blood cells by each device measured by activated partial thromboplastin time and prothrombin time using a coagulometer, prior to processing of the shed blood and after processing with each device

**Completion date**

01/01/2023

## Eligibility

**Key inclusion criteria**

1. Women giving assisted vaginal birth or undergoing caesarean section.
2. Women losing between 500 and 1500 mL of shed blood

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

Female

**Total final enrolment**

11

**Key exclusion criteria**

1. Any patient undergoing caesarean section where cell salvage is clinically indicated and standard practice at West Middlesex University Hospital (i.e. placenta praevia major, the patient is a Jehovah's Witness etc)
2. Any patients with significant haemoglobinopathy (such as sickle-cell or thalassaemia) where red cell fragility may be an issue
3. Any patients taking intrapartum antibiotics
4. Any patient with an active diagnosis of cancer

**Date of first enrolment**

27/07/2021

**Date of final enrolment**

01/01/2023

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Chelsea and Westminster Hospital**

Chelsea and Westminster Hospital NHS Foundation Trust

369 Fulham Road

London

United Kingdom

SW10 9NH

## Sponsor information

**Organisation**

HemoClear B.V.

## Funder(s)

**Funder type**

Government

**Funder Name**

European Commission

**Alternative Name(s)**

European Union, Comisi3n Europea, Europaische Kommission, EU-Kommissionen, Euroopa Komisjoni, EC, EU

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated and/or analysed during the current study will be included in the subsequent results publication.

## IPD sharing plan summary

Other

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No